Advertisement

Supportive Care in Cancer

, Volume 14, Issue 2, pp 109–115 | Cite as

Oxymorphone: a review

  • Eric PrommerEmail author
Review Article

Abstract

Oxymorphone (oxymorphone hydrochloride) (14-hydroxy-dihydromorphinone), a semisynthetic μ-opioid agonist, was first approved by the US Food and Drug Administration in 1959. Oxymorphone is considered a more potent opioid than its parent compound, morphine. Recently, an immediate-release and long-acting oral formulation of this drug was developed that makes oxymorphone a new option in treating moderate to severe pain. This article reviews the pharmacodynamics, pharmacology, and clinical efficacy for this new option in treating moderate to severe pain.

Keywords

Oxymorphone Opioid receptors Opioid Pharmacokinetics 

References

  1. 1.
    Ripamonti C, Zecca E, De CF (1998) Pharmacological treatment of cancer pain: alternative routes of opioid administration. Tumori 84(3):289–300PubMedGoogle Scholar
  2. 2.
    Hanks GW, Twycross RG, Bliss JM (1987) Controlled release morphine tablets: a double-blind trial in patients with advanced cancer. Anaesthesia 42(8):840–844PubMedGoogle Scholar
  3. 3.
    Ripamonti C, Brunelli C (2003) Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 21(14):2801–2802CrossRefPubMedGoogle Scholar
  4. 4.
    Estfan B, LeGrand SB, Walsh D, Lagman RL, Davis MP (2005) Opioid rotation in cancer patients: pros and cons. Oncology (Huntingt) 19(4):511–516Google Scholar
  5. 5.
    Adams M, Pieniaszek HJ Jr, Gammaitoni AR, Ahdieh H (2005) Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J Clin Pharmacol 45(3):337–345CrossRefPubMedGoogle Scholar
  6. 6.
    Ahdieh H, Ma T, Babul N, Lee D (2004) Efficacy of oxymorphone extended release in postsurgical pain: a randomized clinical trial in knee arthroplasty. J Clin Pharmacol 44(7):767–776CrossRefPubMedGoogle Scholar
  7. 7.
    Sloan P, Slatkin N, Ahdieh H (2005) Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. Support Care Cancer 13(1):57–65CrossRefPubMedGoogle Scholar
  8. 8.
    Ananthan S, Khare NK, Saini SK et al (2004) Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydromorphone]. J Med Chem 47(6):1400–1412CrossRefPubMedGoogle Scholar
  9. 9.
    Armstrong SC, Cozza KL (2003) Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality. Part I. Psychosomatics 44(2):167–171CrossRefPubMedGoogle Scholar
  10. 10.
    Hale ME, Dvergsten C, Gimbel J (2005) Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain 6(1):21–28CrossRefPubMedGoogle Scholar
  11. 11.
    Endo Pharmaceuticals (2004) Numorphan package insert. Endo, Chadds FordGoogle Scholar
  12. 12.
    Adams MP, Ahdieh H (2004) Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. Pharmacotherapy 24(4):468–476CrossRefPubMedGoogle Scholar
  13. 13.
    Cheng CY, Hsin LW, Lin YP, Tao PL, Jong TT (1996) N-cubylmethyl substituted morphinoids as novel narcotic antagonists. Bioorg Med Chem 4(1):73–80CrossRefPubMedGoogle Scholar
  14. 14.
    Xu W, Huang LF, Bauer L, Bhargava HN, Dunn WJ III (1999) Synthesis and opiate receptor binding properties of 17-methyl-6,7-dehydro-3,14-dihydroxy-4,5alpha-epoxy-6,7:4′,5′-pyrimidin omorphinans. Bioorg Med Chem Lett 9(23):3375–3380CrossRefPubMedGoogle Scholar
  15. 15.
    Sinatra RS, Harrison DM (1989) Oxymorphone in patient-controlled analgesia. Clin Pharm 8(8):541–544PubMedGoogle Scholar
  16. 16.
    Adams MP, Ahdieh H (2005) Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. Drugs R D 6(2):91–99PubMedGoogle Scholar
  17. 17.
    Thomson Micromedex (2005) Micromedex healthcare series. Thomson Micromedex, Greenwood VillageGoogle Scholar
  18. 18.
    Gourlay GK, Cherry DA, Onley MM et al (1997) Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain. Pain 69(3):295–302CrossRefPubMedGoogle Scholar
  19. 19.
    Sinatra RS, Lodge K, Sibert K et al (1989) A comparison of morphine, meperidine, and oxymorphone as utilized in patient-controlled analgesia following cesarean delivery. Anesthesiology 70(4):585–590PubMedGoogle Scholar
  20. 20.
    Hussain MA, Aungst BJ (1997) Intranasal absorption of oxymorphone. J Pharm Sci 86(8):975–976CrossRefPubMedGoogle Scholar
  21. 21.
    Celleno D, Capogna G, Sebastiani M et al (1991) Epidural analgesia during and after cesarean delivery. Comparison of five opioids. Reg Anesth 16(2):79–83PubMedGoogle Scholar
  22. 22.
    Aldrete JA, Couto da Silva JM (2000) Leg edema from intrathecal opiate infusions. Eur J Pain 4(4):361–365CrossRefPubMedGoogle Scholar
  23. 23.
    Weinberg DS, Inturrisi CE, Reidenberg B et al (1988) Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 44(3):335–342PubMedGoogle Scholar
  24. 24.
    Gourlay GK (2001) Treatment of cancer pain with transdermal fentanyl. Lancet Oncol 2(3):165–172CrossRefPubMedGoogle Scholar
  25. 25.
    Aungst BJ, Blake JA, Rogers NJ, Hussain MA (1990) Transdermal oxymorphone formulation development and methods for evaluating flux and lag times for two skin permeation-enhancing vehicles. J Pharm Sci 79(12):1072–1076PubMedGoogle Scholar
  26. 26.
    Kirvela M, Lindgren L, Seppala T, Olkkola KT (1996) The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 8(1):13–18CrossRefPubMedGoogle Scholar
  27. 27.
    Beaver WT, Wallenstein SL, Houde RW, Rogers A (1977) Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer. J Clin Pharmacol 17(4):186–198PubMedGoogle Scholar
  28. 28.
    Sinatra R, Chung KS, Silverman DG et al (1989) An evaluation of morphine and oxymorphone administered via patient-controlled analgesia (PCA) or PCA plus basal infusion in postcesarean-delivery patients. Anesthesiology 71(4):502–507PubMedGoogle Scholar
  29. 29.
    Gimbel J, Ahdieh H (2004) The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain. Anesth Analg 99(5):1472–1477CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  1. 1.VIP Palliative Care Program Greater Los Angeles Healthcare, Division of Hematology/OncologyUCLA School of MedicineLos AngelesUSA

Personalised recommendations